Catholic University of Leuven, Faculty of Medicine, Herestraat 49, 3000 Leuven, Belgium.
University Hospitals Leuven, Department of Nephrology and Renal Transplantation; Catholic University Leuven, Department of Microbiology, Immunology and Transplantation, Herestraat 49, 3000 Leuven, Belgium.
Transplant Rev (Orlando). 2022 Jul;36(3):100710. doi: 10.1016/j.trre.2022.100710. Epub 2022 Jul 4.
The COVID-19 pandemic has a great impact on solid organ transplant (SOT) recipients due to their comorbidities and their maintenance immunosuppression. So far, studies about the different aspects of the impact of the pandemic on SOT recipients are limited.
This systematic review summarizes the risk factors that make SOT patients more vulnerable for severe COVID-19 disease or mortality and the impact of immunosuppressive therapy. Furthermore, their clinical outcomes, mortality risk, immunosuppression, immunity and COVID-19 vaccination efficacy are discussed.
A systematic search on PubMed was performed to select original articles on SOT recipients concerning the following four topics: (1) mortality and clinical course; (2) risk factors for mortality and composite outcomes; (3) maintenance immunosuppression; (4) immunity to COVID-19 infection and (5) vaccine immunogenicity. Relevant data were extracted, analyzed and summarized in tables.
This systematic review includes 77 articles. Mortality was associated with advanced age. Post-transplantation time or comorbidities were variably identified as independent risk factors for mortality or severe disease. However, generally, no comorbidity was reported as a major risk factor. SOT recipients have a higher risk of acute kidney injury, but no higher rate of mortality compared to non-transplanted patients was found. Immunosuppression was individually adjusted, without leading to high rates of graft dysfunction. Generally, no association between type of immunosuppression and mortality was found. SOT patients established humoral and cellular immune responses after COVID-19 disease comparable to immunocompetent people. At last, SOT patients experience a diminished immune response after two-dose vaccination with SARS-COV-2-mRNA-vaccines.
More research is needed to address the direct effect of COVID-19 disease on the graft in lung transplant recipients, as well as the factors ameliorating the immune response in SOT recipients.
由于合并症和维持性免疫抑制,COVID-19 大流行对实体器官移植(SOT)受者影响巨大。迄今为止,关于大流行对 SOT 受者不同方面影响的研究有限。
本系统综述总结了使 SOT 患者更容易罹患 COVID-19 重症疾病或死亡的风险因素,以及免疫抑制治疗的影响。此外,还讨论了他们的临床结果、死亡率风险、免疫抑制、免疫和 COVID-19 疫苗效力。
对 PubMed 进行系统检索,以选择关于以下四个主题的 SOT 受者的原始文章:(1)死亡率和临床病程;(2)死亡率和复合结局的危险因素;(3)维持性免疫抑制;(4)对 COVID-19 感染的免疫;(5)疫苗免疫原性。提取、分析和总结相关数据制成表格。
本系统综述包括 77 篇文章。死亡率与年龄较大相关。移植后时间或合并症被不同地确定为死亡率或重症疾病的独立危险因素。然而,一般来说,没有合并症被报道为主要危险因素。SOT 受者发生急性肾损伤的风险较高,但与未移植患者相比,死亡率并未升高。免疫抑制被单独调整,并未导致移植物功能障碍的发生率升高。一般来说,未发现免疫抑制类型与死亡率之间存在关联。SOT 患者在感染 COVID-19 后建立了与免疫健全者相当的体液和细胞免疫应答。最后,SOT 患者在接受两剂 SARS-COV-2-mRNA 疫苗接种后,免疫反应减弱。
需要更多的研究来解决 COVID-19 疾病对肺移植受者移植物的直接影响,以及改善 SOT 受者免疫反应的因素。